Loading...
Market
What percentage of patients will show MASH resolution in future Wegovy trials by end of 2025?
2
Resolution / Starting Odds
Less than 60% • 25%
60% to 70% • 25%
70% to 80% • 25%
More than 80% • 25%
Published trial results and Novo Nordisk press releases
Story
Novo Nordisk's Wegovy Shows Significant Improvement in MASH Trial for Liver Disease
Nov 1, 2024, 01:22 PM
Novo Nordisk's semaglutide 2.4 mg, marketed as Wegovy, has demonstrated significant improvements in liver fibrosis and MASH (metabolic-associated steatohepatitis) resolution in the ESSENCE trial. The trial, which involved 1,200 adults, showed that after 72 weeks, 37% of patients treated with semaglutide experienced improvement in liver fibrosis compared to 22.5% on placebo. Additionally, 62.9% of treated patients achieved MASH resolution versus 34.1% on placebo. Wegovy, primarily a weight-loss drug, also showed potential in treating obesity-associated liver disease. The company plans to file for regulatory approvals in the US and EU in the first half of 2025. Detailed results from the ESSENCE trial will be presented at an upcoming scientific conference.
View original story
Similar markets
Approved for MASH treatment • 25%
Approved with conditions • 25%
Not approved • 25%
Decision delayed • 25%
Less than 20% • 25%
20% to 30% • 25%
31% to 40% • 25%
More than 40% • 25%
Yes • 50%
No • 50%
0 • 25%
1-3 • 25%
4-6 • 25%
More than 6 • 25%
Under 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Over 30% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Weight Loss • 25%
Reduced Heart Attack Risk • 25%
Improved Overall Health • 25%
Other • 25%
Under 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Over 30% • 25%
Yes • 50%
No • 50%
< 1 million • 33%
1 - 2 million • 33%
> 2 million • 34%